FDA clears Plavix for additional heart indication

09/10/2006 | United Press International

The FDA has cleared Bristol-Myers Squibb's and Sanofi's Plavix anti-clotting drug for reducing the risk of fatal heart attack and the risk of a recurrent heart attack, stroke or death in patients with acute STEMI. Patients who have survived a STEMI incident, the most severe form of heart attack, are at higher risk of another heart attack, stroke or death.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI